What does pharmaceuticals — other segment items mean?

Captures non-recurring or miscellaneous financial items specific to the Pharmaceuticals segment that do not fit into standard operating categories. This may include restructuring charges, legal settlements, or unique gains/losses.

Baxter International (BAX) Pharmaceuticals — Other segment items

Screener

Other segment segments

Medical Products & Therapies

-$26M-23.8%

Healthcare Systems & Technologies

-$9M-28.6%

Similar metrics at other companies

CCSIReportable Segment — Other segment items

$11.82M+3.6%

KFYRPO — Other segment items

$1.12M-27.2%

KFYEMEA — Other segment items

$234K+14.7%

KFYConsulting — Other segment items

$2.52M-36.7%

KFYDigital — Other segment items

-$43K—

KFYNorth America — Other segment items

-$2.41M—

Other financials

Income statement

See full

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Balance sheet

See full

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Cash flow

See full

Operating cash flow$213.0M+210%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Valuation

See full

Market cap$14.13B+22.3%

Enterprise value$12.33B+22.1%

P/S1.3×+0.2×

Profitability

See full

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

FCF margin3%-2.4pp

Returns & leverage

See full

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:OtherExpenses.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed: Apr 30, 2026, 4:50 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001628280-26-028962

(in millions)	Three Months Ended March 31, 2026 / Medical Products & Therapies	Three Months Ended March 31, 2026 / Healthcare Systems & Technologies	Three Months Ended March 31, 2026 / Pharmaceuticals	Three Months Ended March 31, 2025 / Medical Products & Therapies	Three Months Ended March 31, 2025 / Healthcare Systems & Technologies	Three Months Ended March 31, 2025 / Pharmaceuticals
Net sales	$1,285	$705	$621	$1,262	$704	$581
Cost of sales	781	390	458	694	356	396
Selling, general and administrative expenses	290	209	102	286	217	103
Research and development expenses	54	49	22	59	45	26
Other segment items	(26)	(9)	(7)	(21)	(7)	(7)
Segment operating income	$186	$66	$46	$244	$93	$63

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's pharmaceuticals — other segment items?: Baxter International (BAX) reported pharmaceuticals — other segment items of -$7M in Q1 2026.
How has Baxter International's pharmaceuticals — other segment items changed year-over-year?: Baxter International's pharmaceuticals — other segment items decreased by 0.0% year-over-year, from -$7M to -$7M.
What does pharmaceuticals — other segment items mean?: Captures non-recurring or miscellaneous financial items specific to the Pharmaceuticals segment that do not fit into standard operating categories. This may include restructuring charges, legal settlements, or unique gains/losses.